Traditional herbal medicine as an adjuvant treatment for non-small-cell lung cancer: A systematic review and meta-analysis

Lee, Jungwoo; Kim, Woojin; Min, Byung-Il; Baek, Sun Kyung; Cho, Seung-Hun

doi:10.1016/j.eujim.2015.08.005

Cited by 7 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many studies on the combination of THM and conventional chemotherapy have shown synergistic effects in lung cancer. [ 11 , 13 ] In particular, several clinical reports have indicated that the combination of adjuvant THM and EFGR-TKI, such as gefitinib, in patients with EGFR mutation-positive advanced NSCLC has shown good results, increasing OS and PFS and reducing side effects. [ 12 – 14 ]…”

Section: Discussionmentioning

confidence: 99%

“…[ 10 ] It has been reported that THM is effective as an adjuvant therapy in patients with NSCLC. [ 11 ] In particular, THM combined with EGFR-TKI increases progression-free survival (PFS) and overall survival (OS), improves quality of life, decreases side effects, and delays acquired resistance in patients with advanced NSCLC. [ 11 – 14 ]…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Long-term progression-free survival in a patient with advanced non-small-cell lung cancer treated with low-dose gefitinib and traditional herbal medicine

Lee

Choi³

et al. 2021

Medicine

View full text Add to dashboard Cite

Rationale: Gefitinib is a first-line palliative chemotherapy drug used to treat advanced non-small-cell lung cancer (NSCLC) in patients who have an epidermal growth factor receptor (EGFR) mutation. However, approximately two-thirds of NSCLC patients with EGFR-tyrosine kinase inhibitor experience dermatological toxicity. Cutaneous toxicity is usually not life threatening but can necessitate modification or discontinuation of medication in severe cases. In this case, despite a reduction in the dose of gefitinib due to side effects, combined treatment with modified Bojungikki-tang (BJKIT) increased progression-free survival (PFS) in an advanced NSCLC patient. Patient concerns: An 83-year-old Asian woman presented with chief complaints of chronic cough, dyspnea, weight loss, and anorexia. Diagnoses: The patient was diagnosed with stage IV NSCLC (T2aN3M1), adenocarcinoma with metastasis to the lymph node, brain, and bone based on image scan and biopsy. An EGFR deletion was detected in exon 19. Interventions: The patient was treated with gefitinib (250 mg/d) and traditional herbal medicine, modified Bojungikki-tang (BJIKT). However, after 1 year of combination therapy, gefitinib was tapered down to once per week while modified BJIKT was maintained. Outcomes: A partial response was achieved, but after 3 months severe papulopustular skin rashes developed and became aggravated with time. Thus, the gefitinib dose was reduced. However, the PFS has been maintained for approximately 78 months. Lessons: Despite the reduction in gefitinib dose due to side effects, the combined treatment of gefitinib and the modified BJIKT has maintained a PFS of over 78 months, indicating that modified BJIKT enhanced the anti-cancer effect of gefitinib in a patient with advanced NSCLC harboring the EFGR mutation, and may have delayed acquired resistance, the main limitation on the efficacy of gefitinib. Further investigations including clinical trials are needed to confirm these effects.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Long-term progression-free survival in a patient with advanced non-small-cell lung cancer treated with low-dose gefitinib and traditional herbal medicine

Lee

Choi³

et al. 2021

Medicine

View full text Add to dashboard Cite

show abstract

“…The viscera-related theory is an important guiding theory in clinical practice related to traditional Chinese medicine (TCM), and its investigation has been the focus of research in this field [1][2][3]. The "lung governing skin and hair theory (肺主皮毛) [4,5]" suggests that lung conditions can be evaluated by the observation of cutaneous manifestations and that respiratory system disorders may be responsible for skin lesions [6].…”

Section: Introductionmentioning

confidence: 99%

Association of lung cancer with skin diseases: A nationwide cohort study based on the “lung governing skin and hair” theory

Shen

Lin

et al. 2016

European Journal of Integrative Medicine

View full text Add to dashboard Cite

Nebulizable colloidal nanoparticles co-encapsulating a COX-2 inhibitor and a herbal compound for treatment of lung cancer

Said-Elbahr

Nasr

Alhnan

et al. 2016

European Journal of Pharmaceutics and Biopharmaceutics

View full text Add to dashboard Cite

Traditional herbal medicine as an adjuvant treatment for non-small-cell lung cancer: A systematic review and meta-analysis

Cited by 7 publications

References 22 publications

Long-term progression-free survival in a patient with advanced non-small-cell lung cancer treated with low-dose gefitinib and traditional herbal medicine

Long-term progression-free survival in a patient with advanced non-small-cell lung cancer treated with low-dose gefitinib and traditional herbal medicine

Association of lung cancer with skin diseases: A nationwide cohort study based on the “lung governing skin and hair” theory

Nebulizable colloidal nanoparticles co-encapsulating a COX-2 inhibitor and a herbal compound for treatment of lung cancer

Contact Info

Product

Resources

About